Treating or reducing the incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates a CGRP pathway Methods are disclosed herein. Compositions for use in the disclosed methods are also provided. Antibodies derived from antagonist antibody G1 and G1 directed against CGRP are also described.
展开▼
